Erasca, Inc. (ERAS): Price and Financial Metrics
ERAS Price/Volume Stats
| Current price | $1.85 | 52-week high | $3.45 |
| Prev. close | $1.86 | 52-week low | $1.64 |
| Day low | $1.83 | Volume | 1,389,800 |
| Day high | $1.94 | Avg. volume | 1,520,427 |
| 50-day MA | $2.69 | Dividend yield | N/A |
| 200-day MA | $2.57 | Market Cap | 523.04M |
ERAS Stock Price Chart Interactive Chart >
Erasca, Inc. (ERAS) Company Bio
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of NSCLC, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. The company was incorporated in 2018 and is headquartered in San Diego, California.
ERAS Price Returns
| 1-mo | -27.17% |
| 3-mo | -28.29% |
| 6-mo | -43.43% |
| 1-year | 5.71% |
| 3-year | -83.26% |
| 5-year | N/A |
| YTD | -26.29% |
| 2024 | 17.84% |
| 2023 | -50.58% |
| 2022 | -72.34% |
| 2021 | N/A |
| 2020 | N/A |
Loading social stream, please wait...